Aug 14
|
Asian Growth Companies With High Insider Ownership In August 2025
|
Aug 11
|
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
|
Aug 11
|
Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy
|
Aug 4
|
Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma
|
Jul 31
|
Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC
|
Jul 28
|
Could bispecifics unseat Keytruda from its oncology throne?
|
Jul 28
|
NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
|
Jul 24
|
Exploring Three High Growth Tech Stocks In Asia
|
Jul 24
|
Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer
|
Jul 16
|
3 Asian Growth Companies With High Insider Ownership And 58% Earnings Growth
|
Jul 16
|
Asian Stocks Estimated To Be Trading At Discounts Of Up To 26.6%
|
Jul 16
|
Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
|
Jul 13
|
China Biotech’s Stunning Advance Is Changing the World’s Drug Pipeline
|
Jul 10
|
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal
|
Jul 10
|
Agile Occupational Medicine and Akeso Occupational Health Merge to Form Leading West Coast Occupational Health Platform
|
Jul 9
|
Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal
|
Jun 25
|
High Growth Tech Stocks in Asia for June 2025
|
Jun 16
|
Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
|
May 19
|
Asian Growth Companies With High Insider Ownership
|
May 19
|
Global Value Stocks: 3 Companies That May Be Priced Below Their Intrinsic Estimates
|